678 related articles for article (PubMed ID: 35511238)
1. Human adipose-derived mesenchymal stem cells prevent type 1 diabetes induced by immune checkpoint blockade.
Kawada-Horitani E; Kita S; Okita T; Nakamura Y; Nishida H; Honma Y; Fukuda S; Tsugawa-Shimizu Y; Kozawa J; Sakaue T; Kawachi Y; Fujishima Y; Nishizawa H; Azuma M; Maeda N; Shimomura I
Diabetologia; 2022 Jul; 65(7):1185-1197. PubMed ID: 35511238
[TBL] [Abstract][Full Text] [Related]
2. Human Umbilical Cord Mesenchymal Stem Cells Promote Macrophage PD-L1 Expression and Attenuate Acute Lung Injury in Mice.
Tu C; Wang Z; Xiang E; Zhang Q; Zhang Y; Wu P; Li C; Wu D
Curr Stem Cell Res Ther; 2022; 17(6):564-575. PubMed ID: 35086457
[TBL] [Abstract][Full Text] [Related]
3. Expansion of Pathogenic Cardiac Macrophages in Immune Checkpoint Inhibitor Myocarditis.
Ma P; Liu J; Qin J; Lai L; Heo GS; Luehmann H; Sultan D; Bredemeyer A; Bajapa G; Feng G; Jimenez J; He R; Parks A; Amrute J; Villanueva A; Liu Y; Lin CY; Mack M; Amancherla K; Moslehi J; Lavine KJ
Circulation; 2024 Jan; 149(1):48-66. PubMed ID: 37746718
[TBL] [Abstract][Full Text] [Related]
4. Inflammatory Cell Infiltration Into Islets Without PD-L1 Expression Is Associated With the Development of Immune Checkpoint Inhibitor-Related Type 1 Diabetes in Genetically Susceptible Patients.
Kawata S; Kozawa J; Yoneda S; Fujita Y; Kashiwagi-Takayama R; Kimura T; Hosokawa Y; Baden MY; Uno S; Uenaka R; Namai K; Koh Y; Tomimaru Y; Hirata H; Uemura M; Nojima S; Morii E; Eguchi H; Imagawa A; Shimomura I
Diabetes; 2023 Apr; 72(4):511-519. PubMed ID: 36657987
[TBL] [Abstract][Full Text] [Related]
5. Tonsil-derived mesenchymal stem cells (T-MSCs) prevent Th17-mediated autoimmune response via regulation of the programmed death-1/programmed death ligand-1 (PD-1/PD-L1) pathway.
Kim JY; Park M; Kim YH; Ryu KH; Lee KH; Cho KA; Woo SY
J Tissue Eng Regen Med; 2018 Feb; 12(2):e1022-e1033. PubMed ID: 28107610
[TBL] [Abstract][Full Text] [Related]
6. Immune cells and their inflammatory mediators modify β cells and cause checkpoint inhibitor-induced diabetes.
Perdigoto AL; Deng S; Du KC; Kuchroo M; Burkhardt DB; Tong A; Israel G; Robert ME; Weisberg SP; Kirkiles-Smith N; Stamatouli AM; Kluger HM; Quandt Z; Young A; Yang ML; Mamula MJ; Pober JS; Anderson MS; Krishnaswamy S; Herold KC
JCI Insight; 2022 Sep; 7(17):. PubMed ID: 35925682
[TBL] [Abstract][Full Text] [Related]
7. Expression and role of the immune checkpoint regulator PD-L1 in the tumor-stroma interplay of pancreatic ductal adenocarcinoma.
Daunke T; Beckinger S; Rahn S; Krüger S; Heckl S; Schäfer H; Wesch D; Pilarsky C; Eckstein M; Hartmann A; Röcken C; Wandmacher AM; Sebens S
Front Immunol; 2023; 14():1157397. PubMed ID: 37449210
[TBL] [Abstract][Full Text] [Related]
8. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
9. PD-1, but not PD-L1, expressed by islet-reactive CD4+ T cells suppresses infiltration of the pancreas during type 1 diabetes.
Pauken KE; Jenkins MK; Azuma M; Fife BT
Diabetes; 2013 Aug; 62(8):2859-69. PubMed ID: 23545706
[TBL] [Abstract][Full Text] [Related]
10. B lymphocytes expressing high levels of PD-L1 are key regulators of diabetes development in non-obese diabetic mice.
Chen K; Xue Q; Liu F; Liu L; Yu C; Bian G; Zhang K; Fang C; Song J; Ju G; Wang J
Mol Immunol; 2019 Oct; 114():289-298. PubMed ID: 31419705
[TBL] [Abstract][Full Text] [Related]
11. The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo.
Paterson AM; Brown KE; Keir ME; Vanguri VK; Riella LV; Chandraker A; Sayegh MH; Blazar BR; Freeman GJ; Sharpe AH
J Immunol; 2011 Aug; 187(3):1097-105. PubMed ID: 21697456
[TBL] [Abstract][Full Text] [Related]
12. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
Front Immunol; 2021; 12():654463. PubMed ID: 34054817
[TBL] [Abstract][Full Text] [Related]
13. Programmed death (PD)-1/PD-ligand 1 blockade mediates antiangiogenic effects by tumor-derived CXCL10/11 as a potential predictive biomarker.
Mitsuhashi A; Kondoh K; Horikawa K; Koyama K; Nguyen NT; Afroj T; Yoneda H; Otsuka K; Ogino H; Nokihara H; Shinohara T; Nishioka Y
Cancer Sci; 2021 Dec; 112(12):4853-4866. PubMed ID: 34628702
[TBL] [Abstract][Full Text] [Related]
14. Cytocidal macrophages in symbiosis with CD4 and CD8 T cells cause acute diabetes following checkpoint blockade of PD-1 in NOD mice.
Hu H; Zakharov PN; Peterson OJ; Unanue ER
Proc Natl Acad Sci U S A; 2020 Dec; 117(49):31319-31330. PubMed ID: 33229539
[TBL] [Abstract][Full Text] [Related]
15. Bispecific CD3-HAC carried by E1A-engineered mesenchymal stromal cells against metastatic breast cancer by blocking PD-L1 and activating T cells.
Yang Y; Zhang X; Lin F; Xiong M; Fan D; Yuan X; Lu Y; Song Y; Zhang Y; Hao M; Ye Z; Zhang Y; Wang J; Xiong D
J Hematol Oncol; 2019 Apr; 12(1):46. PubMed ID: 31023384
[TBL] [Abstract][Full Text] [Related]
16. Protective role of programmed death 1 ligand 1 (PD-L1)in nonobese diabetic mice: the paradox in transgenic models.
Wang CJ; Chou FC; Chu CH; Wu JC; Lin SH; Chang DM; Sytwu HK
Diabetes; 2008 Jul; 57(7):1861-9. PubMed ID: 18420489
[TBL] [Abstract][Full Text] [Related]
17. PD-1-dependent restoration of self-tolerance in the NOD mouse model of diabetes after transient anti-TCRβ mAb therapy.
Schroder PM; Khattar M; Baum CE; Miyahara Y; Chen W; Vyas R; Muralidharan S; Mierzejewska B; Stepkowski SM
Diabetologia; 2015 Jun; 58(6):1309-18. PubMed ID: 25794782
[TBL] [Abstract][Full Text] [Related]
18. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
Han X; Li H; Zhou D; Chen Z; Gu Z
Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988
[TBL] [Abstract][Full Text] [Related]
19. Diabetes induced by checkpoint inhibition in nonobese diabetic mice can be prevented or reversed by a JAK1/JAK2 inhibitor.
Ge T; Phung AL; Jhala G; Trivedi P; Principe N; De George DJ; Pappas EG; Litwak S; Sanz-Villanueva L; Catterall T; Fynch S; Boon L; Kay TW; Chee J; Krishnamurthy B; Thomas HE
Clin Transl Immunology; 2022; 11(11):e1425. PubMed ID: 36325490
[TBL] [Abstract][Full Text] [Related]
20. Induction of robust diabetes resistance and prevention of recurrent type 1 diabetes following islet transplantation by gene therapy.
Tian C; Ansari MJ; Paez-Cortez J; Bagley J; Godwin J; Donnarumma M; Sayegh MH; Iacomini J
J Immunol; 2007 Nov; 179(10):6762-9. PubMed ID: 17982066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
